Amwill Health Care Ltd
Incorporated in 2009, Amwill Health Care is in the wholesale trading of pharmaceutical products[1]
- Market Cap ₹ 83.7 Cr.
- Current Price ₹ 41.8
- High / Low ₹ 57.0 / 28.9
- Stock P/E 7.46
- Book Value ₹ 41.6
- Dividend Yield 1.20 %
- ROCE 20.5 %
- ROE 15.3 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.00 times its book value
- Company has delivered good profit growth of 68.1% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.9%
Cons
- Company has high debtors of 177 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| 17 | 26 | 28 | 42 | 37 | 43 | 47 | |
| Sales growth | +52% | +9% | +46% | -10% | +16% | +21% | |
| 18 | 22 | 24 | 25 | 26 | 30 | 35 | |
| Operating Profit | -1 | 4 | 4 | 17 | 12 | 13 | 12 |
| OPM % | -6% | 14% | 15% | 40% | 31% | 30% | 26% |
| 0 | -0 | 0 | 0 | 1 | 3 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | -1 | 3 | 4 | 17 | 12 | 15 | 15 |
| Tax % | -3% | 23% | 25% | 25% | 10% | 26% | |
| -1 | 3 | 3 | 12 | 11 | 11 | 11 | |
| EPS in Rs | -1.06 | 2.73 | 3.31 | 8.01 | 5.36 | 5.71 | 5.60 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 9% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 15% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 68% |
| 3 Years: | 54% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 27% |
| Last Year: | 15% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.05 | 20 | 20 | 20 |
| Reserves | -1 | 1 | 5 | 17 | 49 | 61 | 63 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 9 | 5 | 8 | 2 | 2 | 6 | 5 | |
| Total Liabilities | 8 | 7 | 12 | 19 | 71 | 87 | 88 |
| 1 | 0 | 1 | 1 | 1 | 1 | 1 | |
| CWIP | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 3 | 7 |
| 7 | 6 | 12 | 18 | 70 | 83 | 79 | |
| Total Assets | 8 | 7 | 12 | 19 | 71 | 87 | 88 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 0 | 3 | 5 | -3 | 6 | 8 | |
| -1 | -0 | -1 | -1 | -46 | 6 | |
| 0 | 0 | -0 | -0 | 41 | -0 | |
| Net Cash Flow | -1 | 3 | 3 | -4 | 1 | 14 |
| Free Cash Flow | -1 | 3 | 4 | -4 | 5 | 7 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -26% | 108% | 135% | 6% | 62% | 88% |
Ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 93 | 12 | 16 | 114 | 163 | 177 |
| Inventory Days | 66 | |||||
| Days Payable | 39 | |||||
| Cash Conversion Cycle | 93 | 12 | 16 | 141 | 163 | 177 |
| Working Capital Days | -45 | -25 | -38 | 111 | 166 | 158 |
| ROCE % | 1,069% | 133% | 153% | 28% | 21% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales and Marketing Team Size count |
|
||
| Total Employees count |
|||
| Hair Care Revenue Mix % of total revenue |
|||
| Lip Care Revenue Mix % of total revenue |
|||
| Personal Care & Hygiene Revenue Mix % of total revenue |
|||
| Skin Care Revenue Mix % of total revenue |
|||
| Total Number of Products (SKUs) count |
|||
| Number of States Covered count |
|||
Extracted by Screener AI
Documents
Announcements
-
Disclosuer Under Regulation 30 Of SEBI (LODR) Regulation, 2015
- Committed ₹3 crore on Nov 4, 2026 in Nippon India Credit Opportunities AIF Scheme II.
- Corporate Action-Board approves Dividend
- Disclosure Under Regulation 42 Of SEBI (LODR) Regulations, 2015
-
Approval Of Unaudited Financial Results Of The Company For The Half Year Ended September 30, 2026, For The Financial Year 2026-27.
- Board approved H1 FY27 results, declared ₹0.50 interim dividend, record date October 30, 2026.
-
Board Meeting Outcome for Board Meeting Outcome Of The Meeting Of The Board Held On October 23Rd, 2026.
- Board approved H1 FY27 unaudited results, ₹0.50 interim dividend, record date October 30, 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from web
-
Annual Report 2025
from bse
Business Overview:[1][2]
AHCL specializes in Dermatology, Trichology, and Cosmetology. It develops advanced skincare solutions using high-performance dermatological actives, natural ingredients, and specialized formulation technologies to deliver clinically visible results. Through strategic partnerships with contract manufacturers, distributors, and product development experts, the company maintains capabilities across formulation, packaging, and distribution, while its core operational activities are managed by trusted partners.
The company integrates advanced research, evidence-based formulation technologies, clinically validated ingredients to develop solutions that deliver real, visible results.